Investigating potential sex-specific differences of newer glucose-lowering therapies on cardiovascular outcomes in Victorian patients with diabetes

Sharma, Abhipree; Wood, Stephen; Blasio, Miles De; Bell, Simon; Ilomäki, Jenni; Ritchie, Rebecca H.

doi:10.1016/j.yjmcc.2022.08.009

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the protective effect of SGLT2i appeared to vary based on gender; a study from Australia indicates that older men with baseline HF benefit more from SGLT2i than women (subdistribution HR, 0.78 [95% CI, 0.66 to 0.93] for men; subdistribution HR, 0.99 [95% CI, 0.77 to 1.28] for women). On the contrary, SGLT2i were observed to improve the outcomes of women with baseline ASCVD (subdistribution HR, 0.98 [95% CI, 0.74 to 0.73] for men; subdistribution HR, 0.36 [95% CI, 0.18 to 0.71] for women) (Sharma et al, 2023). In another study, the effect of canagliflozin on cardiovascular events did not differ by age or sex (HR, 0.71 [95% CI, 0.54 to 0.95] for women; HR, 0.69 [95% CI, 0.56 to 0.84] for men; p = 0.8 for interaction) (Yi et al, 2023).…”

Section: Cardiorenal Protection Of Sglt2i Glp-1ras and Dpp-4imentioning

confidence: 97%

Emerging role of antidiabetic drugs in cardiorenal protection

Fu,

Huo,

Mao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

The global prevalence of diabetes mellitus (DM) has led to widespread multi-system damage, especially in cardiovascular and renal functions, heightening morbidity and mortality. Emerging antidiabetic drugs sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4i) have demonstrated efficacy in preserving cardiac and renal function, both in type 2 diabetic and non-diabetic individuals. To understand the exact impact of these drugs on cardiorenal protection and underlying mechanisms, we conducted a comprehensive review of recent large-scale clinical trials and basic research focusing on SGLT2i, GLP-1RAs, and DPP-4i. Accumulating evidence highlights the diverse mechanisms including glucose-dependent and independent pathways, and revealing their potential cardiorenal protection in diabetic and non-diabetic cardiorenal disease. This review provides critical insights into the cardiorenal protective effects of SGLT2i, GLP-1RAs, and DPP-4i and underscores the importance of these medications in mitigating the progression of cardiovascular and renal complications, and their broader clinical implications beyond glycemic management.

show abstract

Section: Cardiorenal Protection Of Sglt2i Glp-1ras and Dpp-4imentioning

confidence: 97%